

PARSORTIX

- Parsortix Inc was founded in 2006 to commercialise technology designed to separate particles at the micro level. As a first application of this technology, Parsortix will develop a device that will assist in prenatal diagnostics. Specifically, this device will collect fetal cells for the detection of spina bifida, Down's syndrome or other diseases associated with chromosomal abnormalities, without the trauma associated with amniocentesis or chorionic villus sampling (CVS). The technology may also have applications in bone marrow transplant therapy during cancer treatment.

□ AT A GLANCE

- Established by ANGLE in 2006
- Based on intellectual property via Ben Franklin Technology Partners
- Currently refining and developing the technology

□ CONTACT DETAILS

David Counts, PhD
Associate Director, US Ventures
1835 Market Street, Suite 1100
Philadelphia, PA 19103

T: 1.215.564.6886
E: dave.counts@angletec.com

□ ABOUT ANGLE

Founded in 1994, ANGLE is an international Consulting, Management and Ventures company focusing on the commercialisation of technology and the development of technology-based industry.

ANGLE Ventures founds, develops and operates its own technology-based businesses. Utilising our in-house Progeny® process, we commercialise intellectual property developed by technology partners in the academic, private and public sectors.



BACKGROUND


This technology was initially developed to aid in the collection of cells for genetic analysis. However, it was recognised that the technology may provide an approach to the collection of fetal cells from maternal blood. As such, Parsortix has experimentally demonstrated that fetal cells can be isolated from maternal blood utilising this technology. Future prenatal diagnostic technologies will also be able to utilise these cells for markers of genetic diseases. The technology provides an

easy, cost effective technique to isolate fetal cells from maternal blood. This isolation technique also shows potential for use in diagnosis and treatment in cancer treatment and disorders of the immune system. ANGLE identified this technology through its collaboration with the Ben Franklin Technology Partners of Southeastern Pennsylvania, and will be exploring co-investing in this opportunity with Ben Franklin.

MARKET OPPORTUNITY

There are approximately 6 million pregnancies annually in the US alone, with 4.5 million live births. Approximately 300,000 women have an invasive amniocentesis or chorionic villus sampling procedure performed as the result of screening for the potential of having a child with chromosomal abnormalities. These procedures collect fetal cells for the diagnostic test. Because Parsortix's technology enables the collection of fetal cells in a non-invasive manner, we believe that Parsortix's technology will initially replace the current method of collecting fetal cells for examination for chromosomal abnormalities. We believe that after initial introduction of Parsortix's technology, later market penetration will permit this technology to replace the current pre-screening blood tests, a current available market of approximately 2.5 million patients per year in the US alone. This fetal cell collection can be performed in the first trimester, thus permitting earlier diagnosis of potential problems which, in turn, will provide for better care of the mother and unborn infant. This will save time and money by proceeding directly to the diagnostic test for birth defects due to chromosomal abnormalities.





Primarily Parsortix will develop a device that will collect fetal cells for the detection of spina bifida, Down's syndrome or other diseases associated with chromosomal abnormalities

□ PARSORTIX MANAGEMENT

Parsortix is currently recruiting key staff to lead its commercialisation and licensing process.

PROGRESS/ACTIVITIES

Parsortix will be working with leading medical geneticists and obstetric and gynecological experts to develop this technology. Parsortix is assembling a team of technologists, scientists and business development specialists to assist in the development of its technology. It is anticipated that Parsortix will begin clinical testing in early 2007 and will be seeking market approval sometimes in 2008.

□ PARSORTIX AND ANGLE

The creation of Parsortix marks a further major extension of ANGLE's Progeny® process which is designed to help companies commercialise the value of their intellectual property. ANGLE itself is a category pioneer, leader and expert in technology wealth creation (TWC). Spanning the worlds of technology, finance and management, ANGLE applies this core expertise in three ways to:

- Enable companies to participate effectively in TWC (Management Services)
- Help firms decide how to optimize and progress the value of their engagement in TWC (Consulting), and finally, as with Parsortix, to
- Deliver successful direct results from TWC (Ventures).

The formation of Parsortix demonstrates ANGLE's ability of work with entrepreneurs to focus the market opportunity for their invention. ANGLE, by focusing on the market opportunity, identifying key issues in commercialisation of the technology, and assembling a team appropriate to bridge the market opportunity and the technology, demonstrates ANGLE's unique ability to enable the launch of a company focused on a commercial goal. This means to the holders and inventors of technology a rapid and high return for their investment.

By isolating fetal cells from maternal blood, Parsortix's particle isolation technology will enable diagnostic tests for chromosomal abnormalities without invasive amniocentesis or chorionic villus sampling. This will permit earlier diagnosis of these abnormalities permitting better planning for the unborn child and mother.

